JP7274469B2 - Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 - Google Patents

Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 Download PDF

Info

Publication number
JP7274469B2
JP7274469B2 JP2020519404A JP2020519404A JP7274469B2 JP 7274469 B2 JP7274469 B2 JP 7274469B2 JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020519404 A JP2020519404 A JP 2020519404A JP 7274469 B2 JP7274469 B2 JP 7274469B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
cells
binding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536109A (ja
JP2020536109A5 (enExample
Inventor
ステファニー・シャントゥー
ニコラ・グルダン
カリーヌ・パトゥレル
イヴァン・ペロ
バンジャマン・ロッシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2020536109A publication Critical patent/JP2020536109A/ja
Publication of JP2020536109A5 publication Critical patent/JP2020536109A5/ja
Application granted granted Critical
Publication of JP7274469B2 publication Critical patent/JP7274469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020519404A 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 Active JP7274469B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US62/568,812 2017-10-06
US201862686143P 2018-06-18 2018-06-18
US62/686,143 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (3)

Publication Number Publication Date
JP2020536109A JP2020536109A (ja) 2020-12-10
JP2020536109A5 JP2020536109A5 (enExample) 2021-10-21
JP7274469B2 true JP7274469B2 (ja) 2023-05-16

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519404A Active JP7274469B2 (ja) 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復

Country Status (11)

Country Link
US (2) US20190218308A1 (enExample)
EP (1) EP3692068B1 (enExample)
JP (1) JP7274469B2 (enExample)
KR (1) KR102710877B1 (enExample)
CN (1) CN111542539B (enExample)
AU (1) AU2018346447B2 (enExample)
BR (1) BR112020006809A2 (enExample)
CA (1) CA3074588A1 (enExample)
IL (1) IL273414B2 (enExample)
SG (1) SG11202002192QA (enExample)
WO (1) WO2019068907A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN115141277A (zh) * 2019-08-21 2022-10-04 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
US12391756B2 (en) 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
EP4076669A4 (en) * 2019-12-19 2024-01-10 Board of Regents, The University of Texas System METHOD FOR TREATING GLIOBLASTOMA
CN114106160A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 抗SARS-CoV-2病毒单克隆抗体及应用
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
AR124906A1 (es) * 2021-02-19 2023-05-17 Janssen Biotech Inc Materiales y métodos para dirigirse a las células t reguladoras para potenciar la vigilancia inmunitaria
TW202302638A (zh) * 2021-02-19 2023-01-16 美商健生生物科技公司 用於靶向調節性ｔ細胞以增強免疫監視之材料及方法
MX2023011031A (es) 2021-03-19 2023-12-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo especificos de linfocitos b.
TW202340243A (zh) 2022-03-03 2023-10-16 美商阿克思生物科學有限公司 抗ｃｄ３９抗體及其用途
CN119403837A (zh) * 2022-06-08 2025-02-07 上海华奥泰生物药业股份有限公司 Cd39/cd73双特异性抗原结合蛋白及其用途
WO2024197020A2 (en) * 2023-03-21 2024-09-26 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof
CN120992939B (zh) * 2025-10-27 2025-12-26 苏州旭光科星抗体生物科技有限公司 一种可溶性cd39蛋白含量检测试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US8865653B2 (en) * 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
JP6405242B2 (ja) * 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
EP3259288B1 (en) 2015-02-20 2026-07-22 Innate Pharma Cd73 blockade
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
LT3399984T (lt) 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
AU2018235092B2 (en) * 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
IL273440B1 (en) * 2017-11-15 2026-08-01 Innate Pharma Strengthening the effect of ATP release
KR20220002959A (ko) * 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
CN114127121B (zh) * 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Also Published As

Publication number Publication date
AU2018346447A1 (en) 2020-03-19
US20190218308A1 (en) 2019-07-18
BR112020006809A2 (pt) 2020-10-06
JP2020536109A (ja) 2020-12-10
IL273414B2 (en) 2026-08-01
SG11202002192QA (en) 2020-04-29
CN111542539A (zh) 2020-08-14
CN111542539B (zh) 2023-10-20
CA3074588A1 (en) 2019-04-11
AU2018346447B2 (en) 2025-06-19
EP3692068A1 (en) 2020-08-12
US20230099801A1 (en) 2023-03-30
EP3692068B1 (en) 2022-12-07
IL273414A (en) 2020-05-31
KR20200060471A (ko) 2020-05-29
WO2019068907A1 (en) 2019-04-11
IL273414B1 (en) 2026-04-01
KR102710877B1 (ko) 2024-09-26

Similar Documents

Publication Publication Date Title
US20230099801A1 (en) Restoration of t cell activity via the cd39/cd73 axis
JP7132981B2 (ja) Ｃｄ７３遮断
KR102584011B1 (ko) 암 치료를 위한 조성물 및 방법
AU2018368541B2 (en) Potentiating the effect of ATP release
US11130817B2 (en) CD73 blocking agents
US20180030144A1 (en) Cd73 blockade
EP3259288A1 (en) Cd73 blockade
CN112334486A (zh) 用于治疗癌症的组合物和方法
EA044293B1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73
EA045378B1 (ru) Усиление эффекта от высвобождения аденозинтрифосфата (атф)
BR112017006464B1 (pt) Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230501

R150 Certificate of patent or registration of utility model

Ref document number: 7274469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250